Pharma Industry Races to Address Trump's Drug Pricing Demands

Pharmaceutical companies are now in a rush to react to the latest demand from U.S. President Donald Trump. He has called for 'binding commitments' to reduce drug prices in the United States.

On Thursday, the administration communicated to 17 key pharmaceutical companies, outlining the actions required to lower prices for American prescriptions to 'most favored nation' status by September 29.

The firms were warned that failing to comply would result in the government utilizing all possible measures to guard American consumers against ongoing high drug cost practices, though no specific steps were mentioned.

Among the recipients of these warnings are some of the largest pharmaceutical companies, including Boehringer Ingelheim, EMD Serono, and Genentech among others.

Friday saw a decline in healthcare stocks as markets reacted to Trump's updated trade tariffs. Shares of Novo Nordisk, the maker of Wegovy, initially dropped by 5% before recovering slightly to stand 1.3% lower by late morning in London.

The mandates specified that all Medicaid patients, who are assisted by the U.S. healthcare program for those with low incomes, should benefit from MFN prices.

Firms were also instructed not to offer cheaper medication in developed countries compared to the U.S. market and to sell directly to American consumers, effectively bypassing pharmacy intermediaries.

President Trump has been a vocal critic of what he views as unfair pricing by pharmaceutical firms, and has vowed to slash U.S. drug costs by as much as 80%.

In a bid to tie American prices to the lower international levels, Trump signed an executive order in May to enforce the MFN policy.

Complexities within the U.S. reimbursement framework and the lack of national price controls are contributing factors to the often higher costs of many pharmaceuticals in the United States.

This recent development occurs as the industry faces possible comprehensive tariffs, previously threatened by Trump to potentially reach 200%.

A number of companies have indicated alignment with some of Trump's issues regarding drug pricing.

AstraZeneca's CEO, Pascal Soriot, mentioned ongoing discussions with U.S. officials regarding the MFN policy and investments in U.S. production, noting a recent $50 billion commitment to the U.S. market.

Soriot expressed to reporters that there are legitimate concerns about pricing, and he believes in the merit of price harmonization as the President suggests.

Novartis CEO, Vas Narasimhan, emphasized that the company is aligned with implementing an MFN strategy to reduce domestic drug costs.

An official from Novo Nordisk stated the company's commitment to improving both accessibility and affordability for patients, and their ongoing efforts to find viable solutions for patient access to necessary medication.

Analysts from JPMorgan issued a statement indicating that the administration's severe message serves as a caution, but ongoing dialogues with the government could give pharmaceutical companies time to adjust.

Seiji Wakao, an analyst, remarked that although the recent ultimatum is seen as severe, it is likely that negotiations continue to occur, minimizing the likelihood of drastic immediate changes in the pharmaceutical landscape.